KIDS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
OrthoPediatrics Corp (KIDS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential for growth in the pediatric orthopedics market and has positive analyst ratings, the recent financial performance and technical indicators suggest a neutral to slightly bearish short-term outlook. Additionally, there are no strong trading signals or significant catalysts to justify immediate action.
The MACD is slightly positive at 0.0221, indicating mild bullish momentum, but it is contracting. RSI is neutral at 40.955, and moving averages are converging, signaling no clear trend. The stock is trading near its support level (S1: 15.863), with resistance at R1: 18.003. Overall, the technical indicators do not suggest a strong buy opportunity.
Hedge funds are increasing their positions, with a 114.29% increase in buying over the last quarter. Analysts have raised price targets recently, with a consensus view of long-term revenue growth and profitability improvements. The company is a leader in pediatric orthopedics with visibility to sustained growth.
No significant insider trading trends. The stock has a 60% chance of declining slightly in the short term (-1.39% next day, -1.61% next week, -0.93% next month). Financial performance in Q4 2025 showed a decline in net income (-37.13% YoY) and EPS (-37.68% YoY), which raises concerns about profitability.
In Q4 2025, revenue increased by 16.97% YoY to $61.6M, and gross margin improved to 73.22% (up 8.43% YoY). However, net income dropped to -$10.1M (-37.13% YoY), and EPS fell to -0.43 (-37.68% YoY), indicating profitability challenges.
Analysts have a positive outlook on the stock, with multiple firms raising price targets (ranging from $20 to $24) and maintaining Buy ratings. They highlight the company's leadership in pediatric orthopedics and its potential for sustained revenue growth and profitability improvements.
